2021年1月26日 · Empagliflozin administration to nondiabetic HFrEF patients significantly improves LV volumes, LV mass, LV systolic function, functional capacity, and quality of life …

2022年11月6日 · A substudy of the Empire HF randomized trial (Empagliflozin in Heart Failure Patients With Reduced Ejection Fraction) showed that empagliflozin assignment was …

This study found that oral EMPA treatment decreases the TAC-induced activation of the Wnt/β-catenin/TCF7L2 signaling, thereby significantly attenuating LV hypertrophy. Furthermore, the …

CONCLUSIONS: Among people with type 2 diabetes mellitus and coronary artery disease, SGLT2 inhibition with empagliflozin was associated with significant reduction in LV mass …

The main finding of EMPA-TROPISM is that empagliflozin significantly reverses and ameliorates LV remodeling as demonstrated by reduced LV volumes, mitigated LV hypertrophy, less …

2019年8月22日 · Among people with type 2 diabetes mellitus and coronary artery disease, SGLT2 inhibition with empagliflozin was associated with significant reduction in LV mass indexed to …

电子探针X射线显微分析仪（Electron Probe X-ray Micro-Analyzer，简写为EPMA或者EMA）简称为电子探针。 作为一种在电子光学和 X射线光谱学 原理的基础上发展而来的高效率分析仪 …

This study aimed to elucidate the underlying mechanisms of the beneficial effects of SGLT2 inhibitors on the failing heart. We generated a left ventricular (LV) pressure overload model in …

2021年5月5日 · EMPA reduces infarct size and yields cardioprotection in non-diabetic rats with ischemic LV dysfunction by an indirect, delayed intrinsic mechanism that also improves …

2021年7月1日 · EMPA treatment reduced ventricular arrhythmia vulnerability and mitigated contractile dysfunction in the global I/R model while improving calcium cycling and …